| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/12/2009 | US20090042785 Compound with Affinity for the Cytotoxic T Lymphocyte-Associated Antigen (Ctla-4) |
| 02/12/2009 | US20090042784 Purification of a Drug Substance of a Factor VII Polypeptide by Removal of DesGla-Factor VII Polypeptide Structures |
| 02/12/2009 | US20090042783 Apo e analogs and methods for their use |
| 02/12/2009 | US20090042782 Diagnostic and therapeutic strategies for conditions associated with the FLJ13639 gene |
| 02/12/2009 | US20090042781 Methods for Treating Diabetes |
| 02/12/2009 | US20090042780 Modified TGF-Beta Superfamily Polypeptides and Related Methods |
| 02/12/2009 | US20090042779 Purified Extract of an Alpha-Amylase Inhibitor From Phytoemagglutinin-Essentially Free Beans, Process for Its Extraction and Compositions Containing It |
| 02/12/2009 | US20090042778 Methods for Suppressing Neovascularization Using Ephrinb2 |
| 02/12/2009 | US20090042777 G-CSF Transferrin Fusion Proteins |
| 02/12/2009 | US20090042776 Fungal immunomodulatory protein (fip) prepared by microorganisms and uses thereof |
| 02/12/2009 | US20090042775 Functional genomics, bioinformatics |
| 02/12/2009 | US20090042774 Parathyroid hormone analogues and methods of use |
| 02/12/2009 | US20090042773 P13 kinase gamma inhibitors for the treatment of anaemia |
| 02/12/2009 | US20090042772 Compounds and methods of treating insulin resistance and cardiomyopathy |
| 02/12/2009 | US20090042771 Dietary lipids for improving skin and coat of pets |
| 02/12/2009 | US20090042770 Branched Chain Amino Acid Chelate |
| 02/12/2009 | US20090042769 Modifications of peptide compositions to increase stability and delivery efficiency |
| 02/12/2009 | US20090042768 Purine derivatives and their use for treatment of autoimmune diseases |
| 02/12/2009 | US20090042270 Activatable recombinant neurotoxins |
| 02/12/2009 | US20090042252 Interferon-alpha polypeptides and conjugates |
| 02/12/2009 | US20090042230 Flea allantoinase proteins and uses thereof |
| 02/12/2009 | US20090042199 Nucleotide sequences coding lymphocyte adhesion protein for use in treatment of autoimmunity, inflammation and infection |
| 02/12/2009 | US20090041869 Method of reducing insect resistant pests in transgenic crops |
| 02/12/2009 | US20090041863 Use of GSK3 inhibitors in combination with radiation therapies |
| 02/12/2009 | US20090041849 Dissolution aids for oral peptide delivery comprising a biguanide |
| 02/12/2009 | US20090041836 Glycolipopeptide and uses thereof |
| 02/12/2009 | US20090041828 Insert for the treatment of dry eye |
| 02/12/2009 | US20090041805 Locally administering botulinum toxin powder to a patient using a using a needleless syringe connected to a tank of compressed inert gas, such as helium, for producing a supersonic gas flow; gold, platinum, tungsten or ice crystal carrier; pain is alleviated within 1 to 7 days of administration |
| 02/12/2009 | US20090041797 Modified toxins |
| 02/12/2009 | US20090041794 Identification of Hla-A2-Presented T-Cell Epitopes Derived from the Oncofoetal Antigen-Immature Laminin Receptor Protein and Uses Thereof |
| 02/12/2009 | US20090041793 Immunostimulatory Compositions and Uses Thereof |
| 02/12/2009 | US20090041791 for linking drug moieties to ligands; comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond |
| 02/12/2009 | US20090041790 Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
| 02/12/2009 | US20090041787 Chemokine receptor antagonists as therapeutic agents |
| 02/12/2009 | US20090041775 Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract |
| 02/12/2009 | US20090041774 Haemophilus influenzae type IV pili |
| 02/12/2009 | US20090041772 Soluble Forms of Hendra and Nipah Virus G Glycoprotein |
| 02/12/2009 | US20090041769 Extracellular domain of CTLA4, with (a) methionine at position 27 and ending with aspartic acid at position 150 (b) an alanine at position 26 and ending with aspartic acid at position 150 ; binds CD80 and/or CD86 with greater avidity; lupus, lupus erythematosus, and lupus nephritis |
| 02/12/2009 | US20090041766 Antibodies for inhibiting blood coagulation and methods of use thereof |
| 02/12/2009 | US20090041764 Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency |
| 02/12/2009 | US20090041760 Retroviral immunotherapy |
| 02/12/2009 | US20090041759 Materials and methods for treating ocular-related disorders |
| 02/12/2009 | US20090041756 121p1f1: a tissue specific protein highly expressed in various cancers |
| 02/12/2009 | US20090041753 Cytokine signaling |
| 02/12/2009 | US20090041752 Compositions and methods for the treatment and diagnosis of immune disorders |
| 02/12/2009 | US20090041751 Sepsis Prevention Through Adenosine Receptor Modulation |
| 02/12/2009 | US20090041750 Treatment of spongiform encephalopathy by increased hydrogen peroxide degradation |
| 02/12/2009 | US20090041748 Fibrinogen-Based Tissue Adhesive Containing an Elastase Inhibitor |
| 02/12/2009 | US20090041747 Compounds for Stabilizing Factor VII Polypeptide Formulations |
| 02/12/2009 | US20090041746 Combination therapy with IgA1 proteases |
| 02/12/2009 | US20090041745 Modulators of paraptosis and related methods |
| 02/12/2009 | US20090041744 Dimeric and Multimeric FVIIa Compounds |
| 02/12/2009 | US20090041743 Sperm-blocking agent composition with contraceptive effect |
| 02/12/2009 | US20090041742 Human dnase ii |
| 02/12/2009 | US20090041741 Modified enzyme and treatment method |
| 02/12/2009 | US20090041740 Cancer treatment by metabolic modulations |
| 02/12/2009 | US20090041739 Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| 02/12/2009 | US20090041738 Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| 02/12/2009 | US20090041732 Survivin Peptides As Cancer Vaccines |
| 02/12/2009 | US20090041731 Treatment for Diabetes |
| 02/12/2009 | US20090041728 Proteoglycan Degrading Mutants for the Treatment of CNS |
| 02/12/2009 | US20090041726 Tumor therapy with high affinity laminin receptor-target vectors and combinations with chemotherapeutic agents |
| 02/12/2009 | US20090041723 useful in the production of a library of pyrazole derivatives for biological screening; Hepatitis C virus (HCV); ease of crystallization, yield, stability, solubility, hygroscopicity and flowability of the resulting bulk drug |
| 02/12/2009 | US20090041722 Indole indane amide compounds useful as cb2 agonists and method |
| 02/12/2009 | US20090041721 Arylalkoxyl hepatitis c virus protease inhibitors |
| 02/12/2009 | US20090041720 Heteroaryl substituted thiazoles |
| 02/12/2009 | US20090041719 Method for screening therapeutic agent for glomerular disorder |
| 02/12/2009 | US20090041718 Methods of Modulating Cytokine Activity; Related Reagents |
| 02/12/2009 | US20090041716 Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| 02/12/2009 | US20090041715 Epothilone Combinations |
| 02/12/2009 | DE202008012716U1 Peptide, die an durch Matrix-Metalloprotease 2 modifiziertes humanes Kollagen IV binden Peptides that bind to modified by matrix metalloprotease 2 human collagen IV |
| 02/12/2009 | DE102007036128A1 Antibiotische Peptide Antimicrobial peptides |
| 02/12/2009 | CA2718472A1 Use of phosphatases to treat neuroblastomas and medulloblastomas |
| 02/12/2009 | CA2696035A1 Treating or preventing rotavirus infection |
| 02/12/2009 | CA2695877A1 Novel .gamma.-secretase inhibitor |
| 02/12/2009 | CA2695830A1 Transferrin variants and conjugates |
| 02/12/2009 | CA2695809A1 Plant bioreactor for the production of interleukin-24 cytokine |
| 02/12/2009 | CA2695805A1 Synthetic pulmonary surfactant peptides |
| 02/12/2009 | CA2695734A1 Use of interleukin-22 in the treatment of fatty liver disease |
| 02/12/2009 | CA2695713A1 Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue |
| 02/12/2009 | CA2695697A1 Protein formulations comprising gdf-5 in aqueous acidic solution |
| 02/12/2009 | CA2695666A1 Anti-hypertensive agent |
| 02/12/2009 | CA2695495A1 Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof |
| 02/12/2009 | CA2695082A1 Peptide boronic acid and boronic ester compounds as proteasome inhibitors |
| 02/12/2009 | CA2694434A1 Treatment of prion protein related diseases |
| 02/12/2009 | CA2694140A1 Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| 02/12/2009 | CA2693504A1 Treatment for obesity |
| 02/12/2009 | CA2693237A1 Composition and method for treatment of reperfusion injury and tissue damage |
| 02/12/2009 | CA2686616A1 New treatment for chemical substance addiction |
| 02/11/2009 | EP2022856A2 Improvements in or relating to binding proteins for recognition of DNA |
| 02/11/2009 | EP2022848A1 A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| 02/11/2009 | EP2022800A2 Compositions for the therapy and diagnosis of ovarian cancer |
| 02/11/2009 | EP2022798A1 Synthetic pulmonary surfactant peptides |
| 02/11/2009 | EP2022505A2 GLP-1, exendin-4, peptide analogs and uses thereof |
| 02/11/2009 | EP2022498A2 Neuroendocrine tumour treatment |
| 02/11/2009 | EP2022492A1 Anti-cancer pharmaceutical composition |
| 02/11/2009 | EP2022276A2 Methods for making a multicomponent hemostatic dressing |
| 02/11/2009 | EP2021502A1 Novel genes and markers in type 2 diabetes and obesity |
| 02/11/2009 | EP2021475A1 High-affinity antagonists of elr-cxc chemokines |
| 02/11/2009 | EP2021474A2 Rage fusion proteins, formulations, and methods of use thereof |